ICON Wins Industry Accolades from TIME Magazine, Forbes and Financial Times in Second Half of 2023
December 18 2023 - 7:15AM
Business Wire
Healthcare intelligence organisation earns
recognition as employer of choice and leading innovator in the
clinical trial industry
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence
and clinical research organisation (CRO), finishes the second half
of 2023 with positive recognition as a top-rated employer and
leader in clinical trial innovation.
In recognition of its Environmental, Social and Governance (ESG)
efforts and as an employer of choice, ICON ranked 88th in TIME’s
list of the World’s Best Companies of 2023, the highest ranking CRO
within the top 750 companies included. The award evaluates
companies using standardised KPIs on sustainability, revenue and
employee satisfaction. ICON was also included on both the Forbes
World’s Best Employers and World’s Top Companies for Women lists
for 2023 and was the only CRO to feature in the ‘Drugs and
Biotechnology’ industry sector for both awards.
For the second year running, ICON received the Financial Times
Leaders in Diversity Award. Selection for the award is primarily
based on employee opinions of their own employer’s diversity and
inclusion practices as well as those adopted by other prominent
employers in their respective industries. This year, three
objective indicators were added to calculate final scores: share of
women in management positions, communications made in favour of
diversity, and a diversity score calculated by data provider
Denominator.
ICON’s commitment to generating opportunities for all
stakeholders through sustainable growth and embracing emerging
technologies was recognised by the Frost & Sullivan Institute,
which presented ICON with the ‘2023 Enlightened Growth Leadership
Award’.
Steve Cutler, CEO, ICON noted: “ICON works hard to build an
environment that nurtures growth and success for all. These awards
also recognise our commitment to achieving our ESG goals by
operating as sustainably as possible, creating an inclusive
workplace, driving better patient outcomes, and ensuring the
highest ethical standards across all our operations.”
ICON’s employees were also individually recognised for their
significant contributions to the industry. Rose Kidd, President,
Operations Delivery was included on the PharmaVoice 100 list, which
recognises the most inspiring life sciences leaders. Multiple ICON
employees and teams were recognised for their excellent performance
during the year in the PharmaTimes’ Clinical Researcher of the Year
– The Americas 2023 awards. ICON was also named PharmaTimes’
'Clinical Research Company of the Year'.
In acknowledgement of its leading work in digital innovation,
ICON was awarded a Silver Stevie® Award at the 21st Annual
International Business Awards for its AI tool, ‘Cassandra’. This
harnesses real-world data to predict the requirements of US Food
& Drug Administration (FDA) and European Medicines Agency (EMA)
post-marketing studies. Additionally, ICON’s Independent Data
Monitoring Committee and Endpoint Adjudication (IDEA) group was
honoured with the 2023 AG Mednet ‘Judi Innovation’ Award for its
efforts in optimising and accelerating clinical trial processes
through collaboration and innovation.
ICON’s excellence in developing creative and strategic marketing
campaigns was spotlighted at the 2023 MarCom Awards. The company
was recognised with one Platinum and two Gold Marcom Awards in the
strategic communications category. At the Graphic Design USA
awards, it was a recipient of two Health + Wellness Design Awards.
Furthermore, at the 2023 Rx Club Show Awards, ICON was an award
winner in the print, interactive and video category.
A full list of ICON’s industry awards can be viewed at
www.iconplc.com/awards/.
Ends
About ICON plc
ICON plc is a world-leading healthcare intelligence and clinical
research organization. From molecule to medicine, we advance
clinical research providing outsourced services to pharmaceutical,
biotechnology, medical device and government and public health
organisations. We develop new innovations, drive emerging therapies
forward and improve patient lives. With headquarters in Dublin,
Ireland, ICON employed approximately 41,150 employees in 106
locations in 53 countries as at September 30, 2023. For further
information about ICON, visit: www.iconplc.com.
ICON/ICLR-G
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231218732293/en/
Claire Quinn (GMT time zone) Corporate Communications, ICON plc
claire.quinn@iconplc.com +353 87 4066091 Weber Shandwick (PR
adviser) Lisa Henry (GMT time zone) +447785 458203
lhenry@webershandwick.com
ICON (NASDAQ:ICLR)
Historical Stock Chart
From Jun 2024 to Jul 2024
ICON (NASDAQ:ICLR)
Historical Stock Chart
From Jul 2023 to Jul 2024